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Abstract
Background: Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus
Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency,
whereas depressive conditions of the immune system impair the capability to resolve the infection and allow
reactivation from sites of latency of the parasite.
Case presentation: We describe a case of visceral leishmaniasis (VL) that occurred in a patient with chronic
hepatitis C treated with direct-acting antiviral drugs (DAA). The hypothesized mechanism is the alteration of
protective inflammation mechanisms secondary to DAA therapy. Downregulation of type II and III IFNs, their
receptors, which accompany HCV clearance achieved during treatment with sofosbuvir and ribavirin might have a
negative impact on a risk for reactivation of a previous Leishmania infection. We know indeed that IFN-γ is
important to enhance killing mechanisms in macrophages, which are the primary target cells of Leishmania.
Conclusion: Since VL is endemic in Sicily as well as in other countries of the Mediterranean basin, physicians
should be aware of the possible unmasking of cryptic Leishmania infection by DAAs.
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Background
Visceral leishmaniasis (VL) is a vector-borne parasitic
disease caused by protozoa belonging to the genus Leish-
mania. The clinical presentation of visceral leishmaniasis
strictly depends on the host immunocompetency and
ranges from asymptomatic to severe forms characterized
by fever, splenomegaly and pancytopenia. Depressive
conditions of the immune system such as HIV infection,
immunosuppressive treatments, and cirrhosis impair the
capability of the immune response to resolve the infec-
tion and allow reactivation from sites of latency of the
parasite [1–4]. VL has also been reported during pegy-
lated interferon therapy for chronic hepatitis C [5]. Over
70 million people worldwide are chronically infected
with hepatitis C virus (HCV) and it is estimated that in
Sicily there is a burden of at least 150,000 HCV infected
patients: since 2015 almost 10,000 patients were treated
with direct-acting antiviral agents (DAA) [6]. IFN-free
DAA combination therapies for HCV are oral regimens
that are well tolerated, and typically induce rapid and
sustained viral response (SVR) [7]. Anyway the effect of
DAA on the incidence of other infections in clinical
practice is still unclear. We describe here a case of VL
that occurred in a patient with chronic hepatitis C
treated with DAA.
Case presentation
A Sicilian seventy-year-old man was admitted to the
Infectious Diseases Unit of the University Hospital of
Palermo (Sicily, Italy) in July 2017 referring progressive
asthenia and irregular fever not responsive to antibiotic
therapy lasting 2 months. The patient suffered from dia-
betes mellitus, mild kidney disease, and HCV-related
liver cirrhosis (Child-Pugh B7), for which had been
treated with sofosbuvir and ledipasvir for 24 weeks until
December 2015.
About 3 months later the end of the HCV-treatment,
the patient suffered from a marked worsening of
thrombocytopenia, not considered related to liver cir-
rhosis and not responding to steroid therapy for which
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he had been treated with romiplostim whenever platelet
count was under 20,000/mmc.
At admission in our division, the patient had fever (BT
37.8°) with a pulse rate of 78 bpm, blood pressure and
respiratory rate were normal. No other symptoms were
reported except asthenia. At the physical examination he
had no respiratory alterations, systolic heart murmur at
apex (grade II/VI), hepatosplenomegaly and grade
1-encephalopathy with bradilalia and minimal flapping
tremor.
Laboratory tests revealed pancitopenia (WBC 3100/
mmc -neutrophils 46%, lymphocytes 33%-, Hb 8.1 g/dl,
platelets 46,000/mmc), an increased C-reactive protein
(33 mg/l), D-dimer 6980 UI/l and INR 1.5, eGFR 63ml/
min/1.73m2, AST/ALT 2xN, modest hypoalbuminemia
with polyclonal gammopathy.
The abdominal ultrasound exam showed an increase
in splenomegaly (17 cm) compared to the previous ultra-
sonography from 1 month earlier (14.5 cm). Thoracic
CT scanning was normal. Trans-thoracic echocardiography
excluded vegetations. Blood culture, brucellosis serology,
HIV-IgG and HBsAg were negative. Leishmania serology
resulted positive in enzyme-linked-immunosorbent-assay
(IgG 1:12800), immunofluorescent antibody test (IgG
1:25600) performed as previously described [2] (Table 1)
and Western Blot.
Leishmania infantum DNA was detected in peripheral
blood by Real-time Polymerase Chain Reaction (PCR)
targeted on a 117 bp fragment in the mini circle kineto-
plast DNA (kDNA), carried out as previously described
by Vitale et al. [8].
A bone marrow aspirate was not performed because of
low platelet count. Liposomal amphotericin B was
started at the dose of 3 mg/kg from day 1 to 5 and a fur-
ther dose on day 10 for a total dose of 18 mg/kg.
The blood cells count and the clinical conditions of
the patient progressively improved until reaching normal
values; L. infantum real-time PCR on peripheral blood at
the end of the treatment was negative.
Discussion and conclusions
It is well known that T-cell-dependent immune response
and macrophage activation play a major role during
primary Leishmania infection or reactivation of latent
infection, in addition the effect of DAA on the host
immune status has also recently been addressed [1, 7]. It
has been well documented that DAA regimens are
associated to lower side-effects and higher rate of SVR
obtained in a shorter time frame than interferon and ri-
bavirin. However, some researchers are now discovering
an increased rate of de novo and recurrent hepatocellu-
lar carcinoma (HCC) in patients with HCV cirrhosis
compared to interferon treatment protocols. The hy-
pothesized mechanisms is that inflammation secondary
to chronic HCV infection plays a role in immunosurveil-
lance. DAA therapy seems to abolish this protective and
antineoplastic effect [9]. Moreover, Meissner et al. dem-
onstrated that treatment with sofosbuvir and ribavirin is
associated to downregulation of type II and III IFNs,
their receptors and interferon stimulated genes in liver
[10]. This might have a negative impact on immune con-
trol allowing reactivation of a previous infection. HBV
reactivation occurs frequently in patients with chronic
HBV and HCV coinfection receiving DAA therapy. It is
therefore important to have all patients screened for evi-
dence of overt or occult HBV infection and properly
manage the coinfection during DAAs therapy [11].
We know that IFN-γ is important to enhance killing
mechanisms in macrophages, which are the primary
target cells of Leishmania as well as other intracellular
infections such as tuberculosis. Consequently, a potential
risk for reactivation of a previous Leishmania or Myco-
bacterium tuberculosis infection during DAA therapy is
possible [12]. Since VL is endemic in Sicily as well as in
other countries of the Mediterranean basin, and physi-
cians should be aware of the possible unmasking of
cryptic Leishmania infection after DAAs therapy. Even if
this risk is not considered as a contraindication for
anti-HCV treatment, baseline screening could be sug-
gested when this treatment is started in these epidemio-
logical settings.
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Table 1 Serological tests indicating L. infantum infection
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